Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger
Recce Pharmaceuticals (ASX:RCE) has been on a tear this year. It's developing anti-infective, R327, with clinical results across Diabetic Foot Infection, Acute Bacterial Skin & Skin Structure Infection, and, Urosepsis/UTIs which point to a potential commercial value proposition. It also has a recent key relationship in Indonesia.
Corporate Spotlight
Not Yet Available
Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.
Latest Threads
Tag | Subject | ||||||
---|---|---|---|---|---|---|---|
SXT | New code LPE from now on - please switch to LPE | 29/12/15 | 3 | 3.7K | |||
|
|||||||
SXT | Ann: Becoming a substantial holder | 23/12/15 | 0 | 975 | |||
|
|||||||
SXT | Ann: LPE Acquisition and Requotation Update | 23/12/15 | 3 | 2.7K | |||
|
|||||||
SXT | Come on ASX | 22/12/15 | 0 | 698 | |||
|
|||||||
SXT | Ann: Initial Director's Interest Notice x 2 | 21/12/15 | 4 | 3.1K | |||
|
|||||||
SXT | Ann: Final Director's Interest Notice x 2 | 21/12/15 | 4 | 2.5K | |||
|
|||||||
SXT | Ann: Change of Director's Interest Notice | 18/12/15 | 0 | 749 | |||
|
|||||||
SXT | Ann: SXT Successfully Completes $6m Raise | 18/12/15 | 28 | 14K | |||
|
See All Discussions